中国医药：子公司天方药业获得达比加群酯胶囊药品注册证书

Core Viewpoint - The company Tianfang Pharmaceutical, a wholly-owned subsidiary of China Pharmaceutical, has received approval from the National Medical Products Administration for two drug registration certificates for Dabigatran Etexilate Capsules, indicating a significant advancement in its product pipeline [1] Group 1 - The National Medical Products Administration accepted the registration application for the drug in May 2024 [1] - The total investment in the raw materials and formulation projects for this drug has reached approximately 28 million RMB (unaudited) [1]